Approval · Notice of Compliance 8213 · 2006
RISPERIDONE: Notice of Compliance 8213
Issued August 17, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8213
- Date
- August 17, 2006
- Company
- Genpharm Inc.Etobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Antipsychotic agent
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RISPERIDONE | 02284871 | — |
| RISPERIDONE | 02284898 | — |
| RISPERIDONE | 02284901 | — |
| RISPERIDONE | 02284928 | — |
| RISPERIDONE | 02284936 | — |
| RISPERIDONE | 02284944 | — |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB